The first human report of mobile colistin resistance gene, mcr-1, in Finland

KIRSI GRÖNDAHL-YLI-HANNUKSELA,1 EMILIA LÖNNOVIST,1 TEEMU KALLONEN,2 LAURA LINDHOLM,3 JARI JALAVA,4 KAISU RANTAKOKKO-JALAVA5 and JAANA VUOPIO1

1Institute of Biomedicine, Research Center for Cancer, Infections and Immunity, University of Turku, Turku, Finland; 2Department of Biostatistics, University of Oslo, Oslo, Norway; 3National Institute for Health and Welfare, Expert Microbiology Unit; 4National Institute for Health and Welfare, Infectious Disease Control and Vaccinations, Helsinki; and 5Clinical Microbiology Laboratory, Turku University Hospital, Turku, Finland

Gröndahl-Yli-Hannuksela K, Lönnqvist E, Kallonen T, Lindholm L, Jalava J, Rantakokko-Jalava K, Vuopio J. The first human report of mobile colistin resistance gene, mcr-1, in Finland. APMIS 2018; 126: 413–417.

Colistin resistance mediated by mobile mcr-1 gene has raised concern during the last years. After steep increase in mcr-1 reports, other mcr-gene variants (mcr-2 to mcr-5) have been revealed as well. In 2016, a clinical study was conducted on asymptomatic stool carriage of extended spectrum beta-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae among Finnish adults. All suspected ESBL producing bacterial isolates were first tested by phenotypic ESBL-confirmation methods, and then further analyzed with whole genome sequencing to identify the resistance genes. We found one study subject carrying a colistin resistant E. coli with a transferrable mcr-1 gene. This multi-drug resistant isolate, although initially suspected to be an ESBL producer, did not carry any ESBL genes, but was proven to carry several other resistance genes by using whole genome sequencing. Sequence type was ST93. The mcr-1 gene was connected to IncX4 plasmid which suggests that the colistin resistance gene locates in the respective plasmid. Here, we report the finding of a mcr-1 harboring human E. coli isolate from Finland. Clinical antimicrobial resistance (AMR) rates are low in Finland, and mobile colistin resistance has not been reported previously. This highlights the importance of AMR surveillance also in populations with low levels of resistance.

Key words: antimicrobial resistance; carriage; Escherichia coli; colistin; mcr-1.

Kirsi Gröndahl-Yli-Hannuksela, Institute of Biomedicine/Research Center for Cancer, Infections and Immunity, University of Turku, Turku, Finland. e-mail: kagron@utu.fi

The global spread of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBL) and carbapenemases (CPE) has limited the options of suitable antibiotics for the treatment of infections caused by these gram-negative bacteria. A new chapter in the era of emerging antimicrobial resistance started in 2015 when Liu et al. reported the first finding of transferable plasmid-encoded colistin resistance in Enterobacteriaceae isolated from humans and animals (1). Colistin is considered as the last resort of treatment against multi-drug resistant bacteria. Since the first report from China, several countries from five continents, have detected the mcr-1 gene in Enterobacteriaceae isolated from humans, animals or the environment (2, 3). Sporadic findings of mcr-1 carrying isolates have previously been reported from three other Nordic countries, namely Sweden, Norway and Denmark (4–6). After the first wave of mcr-1 reports, several countries including Denmark from the Nordic countries, have identified isolates carrying new gene variants of mcr gene (currently mcr-1 to mcr-5) (7, 8). In Finland, the overall antimicrobial resistance level has remained relatively low, and use of colistin is reserved for only very rare clinical indications. Now we report the first Escherichia coli isolate from Finland with colistin resistance mediated by mcr-1 gene.

MATERIALS AND METHODS

During 2016, we conducted a prospective, clinical study to investigate asymptomatic fecal ESBL carriage in...
Southwest Finland as part of the Northern Dimension Antibiotic Resistance Study (NoDARS, http://www.ndphs.org/?database,view,project,1468). Fecal samples were collected from 176 healthy, anonymous volunteers, and the samples were screened for ESBL producing *E. coli* and *K. pneumoniae* from ESBL specific chromogenic media (unpublished data). Antimicrobial susceptibility testing (AST) was performed for all isolates according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints (version 6.0, http://www.eucast.org/clinical_breakpoints/). Minimal inhibitory concentration for colistin was preliminarily determined with a gradient strip test (Liofilchem, Roseto degli Abruzzi, Italy) and confirmed by broth microdilution (Thermo Scientific™ Sensititre™ System, Thermo Scientific, East Grinsted, England). Strains with reduced susceptibility to third generation cephalosporins were tested for ESBL production with the combination disk test according to EUCAST recommendations.

To analyze the molecular mechanisms of ESBL, all phenotypically confirmed *E. coli* and *K. pneumoniae* ESBL isolates were analyzed using paired-ended (2 × 150 bp) whole-genome sequencing (WGS) with Illumina MiSeq platform. ResFinder (database version 2.1) (9) and *in silico* PCR, using previously reported primers (10), were used to identify the resistance genes and plasmid replicons from the WGS data. The reads of the *E. coli* isolate carrying *mcr-1* gene have been deposited in NCBI SRA database under the accession numbers SRR6656065.

RESULTS

During our clinical screening study (Ny et al. unpublished data), we decided to extend our analysis by whole genome sequencing all phenotypically confirmed ESBL isolates (*E. coli* and *K. pneumoniae*). The analysis revealed that one of the *E. coli* isolates carried the *mcr-1* gene. The WGS analysis also revealed that the only acquired β-lactam resistance genes found from this isolate were *blaTEM-1b* and *blaCMY-2*.

*Mcr-1* gene and the IncX4 replicon were connected in the de Bruijn graph of the assembly which was visualized with Bandage (11). This strongly suggests that *mcr-1* is located in an IncX4 plasmid. The close proximity region of *mcr-1* gene is illustrated in Fig. 1.

The strain belonged to sequence type (ST) 93. Colistin resistance was confirmed both by the gradient strip test and microdilution methods. All detected plasmid replicons, antimicrobial resistance genes and the AST panel of this isolate are listed in Table 1.

The *mcr-1* carrying *E. coli* was isolated from a fecal sample of a 26 year old healthy male. The exclusion criteria for the study included antibiotic treatment 3 months prior to sampling. Previous usage of antibiotics was not recorded. A background questionnaire revealed that he had travelled to Central Europe and South-America within 6 months before the sampling.

DISCUSSION

During the last years there has been a vast expansion of reports on findings of colistin resistant organisms in humans without prior colistin therapy or clonal transmission (12). Many of these arise from retrospective surveys that have screened past clinical or environmental sample collections for the *mcr-1* gene. Our finding was isolated from a healthy volunteer in 2016. Stool carriage of *mcr-1* gene has been reported from healthy individuals in Europe at least from the Netherlands, Switzerland and Sweden (4, 13, 14). Other reports are from China, Laos and Thailand (12). Of the Nordic countries, Norway and Denmark have both also reported of finding of *Enterobactericeae* isolates carrying *mcr-1* from clinical sample collections (5, 6). A recent publication from Norway, a Nordic country with very low usage of colistin, detected two ESBL producing *E. coli* isolates carrying *mcr-1* gene from environmental samples collected in 2010 (15).

Although the phenotypic characterization of the isolate reported here suggested it to be an ESBL and AmpC producer, it did not carry any classical

![Fig. 1. Structure of the mcr-1 gene region (SRA accession number SRR6656065).](image-url)
ESBL genes based on WGS analysis. However, the isolate can be considered as multi-drug resistant based on criteria by Magiorakos et al. (16). Instead of ESBL genes, the isolate carried a *bla*CMY-2 gene which encodes for a plasmid-mediated AmpC β-lactamase. This specific *bla*CMY-2 gene has especially been reported from animal isolates, mainly from poultry (17). ST-93 is found both from human and animal sources (https://enterobase.warwick.ac.uk/). The plasmid composition and location of the *mcr-1* gene in IncX4 resembles an isolate that has been reported from a pig in Austria (18). Recent studies from Sweden (19) and Norway (20) have identified close genetic relatedness of *E. coli* isolates carrying the *bla*CMY-2 gene both from human samples and retail poultry meat, which suggests a possible common source. The source of the Finnish *mcr-1* *E. coli* isolate, however, remains unknown.

Antimicrobial resistance is routinely monitored from clinical bacterial isolates in Finland. Based on our latest nation-wide antimicrobial report (Finres 2016; http://urn.fi/URN:ISBN:978-952-302-958-3), antimicrobial susceptibility of *E. coli* isolates from bacteremic cases is still relatively good. Resistance to third generation cephalosporins is 5–6% in *E. coli* blood isolates. However, the rates have

---

### Table 1. Characteristics of the *Escherichia coli* isolate carrying *mcr-1* gene. Antimicrobial susceptibility testing was performed with disk diffusion method, in addition, MIC testing for fosfomycin with Etest and for colistin with Etest and Sensititre.

| Antimicrobial class | Antimicrobial agent | Zone diameter (mm) or MIC (µg/ml) | S/R¹ | Resistance genes | Combination disk test | Zone diameter (mm) | Plasmids |
|---------------------|---------------------|-----------------------------------|------|------------------|-----------------------|---------------------|----------|
| Penicillin          | Ampicillin          | 6                                 | R    | *bla*TEM-1B, *bla*CMY-2 | Cefotaxime/ Cefotaxime + clavulanic acid | 19/24               | ColRNAI  |
|                     | Amoxicillin         | 11                                | R    |                   | Cefazidim/ Cefazidim + clavulanic acid | 16/14               | ColRNAI  |
| 2ⁿ generation cephalosporin | Cefoxitin       | 10                                | R    |                   | Cefotaxim/ Cefotaxim + clavulanic acid | 23/32               | IncFII   |
| 3ⁿ generation cephalosporin | Cefotaxime     | 13                                | R    |                   | Cefazidim/ Cefazidim + clavulanic acid | 21/31               | IncX4    |
| Carbapenem          | Cefazidime         | 14                                | R    |                   |                       | H                  | FIB      |
| Fluoroquinolone     | Meropenem          | 33                                | S    |                   |                       |                    |          |
|                     | Ciprofloxacin      | 24                                | S    | qnrB19            | Quinolone resistance  |                    |          |
| Trimethoprim        | Trimethoprim       | 6                                 | R    | dfrA8             | Trimethoprim resistance |                   |          |
|                     | Trimethoprim-sulfamethoxazole | 13                  | R    |                  |                       |                    |          |
| Aminoglycoside      | Gentamicin          | 21                                | S    |                   | mcr-1                 | Colistin resistance |          |
| Polymyxin           | Colistin           | 3²/4¹                            | R    | strA, strB        | Kanamycin, neomycin, paromycin, streptomycin resistance |          |          |
| Other               | Nitrofurantoin     | 22                                | S    | sul2              | Sulfonamide resistance |          |          |
|                     | Temocillin         | 27                                | –    | flOR              | Florfenicol/ chloramphenicol resistance |          |          |
|                     | Fosfomycin         | 0.38                              | S    |                   |                       |                    |          |
|                     | Mecillinam         | 22                                | S    |                   |                       |                    |          |

¹Interpretation according to EUCAST clinical breakpoints. S = sensitive, R = resistant, – = no currently available breakpoint.
²As determined by Etest (µg/ml).
³As determined by Sensititre (µg/ml).
shown an increase during the last few years. National Institute for Health and Welfare has retrospectively screened all CPE isolates \( n = 145 \) found from Finland between 2008–2015 for the \( mcr-1 \) gene. No such isolates have been found (unpublished data). Our current \( mcr-1 \) finding is not from a clinical case but from a healthy volunteer. AST for colistin is routinely often limited to the most resistant strains, i.e. those with reduced susceptibility to carbapenems. In the lack of an easy screening test, the presence of transferrable colistin resistance may remain undetected in strains fully susceptible to carbapenems.

We detected the presence of \( mcr-1 \) only in WGS, which may prove a reliable means to detect transferrable colistin resistance. Our report clearly highlights the presence of transferrable colistin resistance among human non-ESBL producing \( E. coli \) isolates also in countries with proven history of low rates of antimicrobial resistance or colistin use.

ETHICS

The study was conducted in accordance with the Declaration of Helsinki and national and institutional standards. Written informed consent was obtained from all study participants. Study design was approved by Ethics Committee, Hospital District of Southwest Finland (ETMK 157/2015).

We thank Mari Virta for excellent technical assistance.

FUNDING

This work was supported by Ministry of Social Affairs and Health; Hospital District of Southwest Finland and partly by European Union: Regional East Action Programme 2013 Part 2, Northern Dimension funds (Grant Contract 2014/344-660 (NoDARS)).

TRANSPARENCY DECLARATIONS

None to declare.

REFERENCES

1. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016;16:161–8.
2. Baron S, Hadjadi L, Rolain JM, Oluaitan AO. Molecular mechanisms of polymyxin resistance: knowns and unknowns. Int J Antimicrob Agents 2016;48:583–91.
3. Ellem JA, Ginn AN, Chen SC, Ferguson J, Partridge SR, Iredell JR. Locally acquired mcr-1 in Escherichia coli, Australia, 2011 and 2013. Emerg Infect Dis 2017;23:1160–3.
4. Vading M, Kabir MH, Kalin M, Iversen A, Wiklund S, Naueler P, et al. Frequent acquisition of low-virulence strains of ESBL-producing Escherichia coli in travellers. J Antimicrob Chemother 2016;71:3548–55.
5. Hasman H, Hammerum AM, Hansen F, Hendriksen RS, Olesen B, Agero Y, et al. Detection of mcr-1 encoding plasmid-mediated colistin-resistant Escherichia coli isolates from human bloodstream infection and imported chicken meat, Denmark 2015. Euro Surveill 2015;20 pii = 30085.
6. Solheim M, Bohlin J, Ulstad CR, Schau Slettemeas J, Nuseer U, Dahle UR, et al. Plasmid-mediated colistin-resistant Escherichia coli detected from 2014 in Norway. J Antimicrob Agents 2016;48:227–8.
7. Kluytmans J. Plasmid-encoded colistin resistance: mcr-one, two, three and counting. Euro Surveill 2017;22 pii: 30588.
8. Roer L, Hansen F, Stegger M, Sonksen UW, Hasman H, Hammerum AM. Novel mcr-3 variant, encoding mobile colistin resistance, in an ST131 Escherichia coli isolate from bloodstream infection, Denmark, 2014. Euro Surveill 2017;22:22846.
9. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother 2012;67:2640–4.
10. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Thrummy EJ. Identification of plasmids by PCR-based replicon typing. J Microbiol Methods 2005;63:219–28.
11. Wick RR, Schultz MB, Zobel J, Holt KE. Bandage: interactive visualization of de novo genome assemblies. Bioinformatics 2015;31:3350–2.
12. Oluaitan AO, Morand S, Rolain JM. Emergence of colistin-resistant bacteria in humans without colistin usage: a new worry and cause for vigilance. Int J Antimicrob Agents 2016;47:1–3.
13. Zurfluh K, Stephan R, Widmer A, Poirel L, Nordmann P, Nuesch HJ, et al. Screening for fecal carriage of MCR-producing Enterobacteriaceae in healthy humans and primary care patients. Antimicrob Resist Infect Control 2017;6:28-017-0186-z.
14. von Wintersdorff CJ, Wolfers PF, van Niekerk JM, Beuken E, van Alphen LB, Stobberingh EE, et al. Detection of the plasmid-mediated colistin-resistance gene mcr-1 in faecal metagenomes of Dutch travellers. J Antimicrob Chemother 2016;71:3416–9.
15. Jorgensen SB, Soraas A, Arnesen LS, Leegaard T, Sundsfjord A, Jenum PA. First environmental sample containing plasmid-mediated colistin-resistant ESBL-producing Escherichia coli detected in Norway. APMIS 2017;125:822–5.
standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–81.

17. Ewers C, Bethe A, Semmler T, Guenther S, Wieler LH. Extended-spectrum beta-lactamase-producing and AmpC-producing Escherichia coli from livestock and companion animals, and their putative impact on public health: a global perspective. Clin Microbiol Infect 2012;18:646–55.

18. Jelovcan S, Leekitcharoenphon P, Weissensteiner G, Hendriksen RS, Lassnig H, Allerberger F, et al. Detection of plasmid-mediated colistin resistance (mcr-1) in E. coli isolated from pig caecum in Austria. Int J Infect Dis 2016;53:44.

19. Borjesson S, Ny S, Egervara M, Bergstrom J, Rosenberg A, Englund S, et al. Limited dissemination of extended-spectrum beta-lactamase- and plasmid-encoded AmpC-producing Escherichia coli from food and farm animals, Sweden. Emerg Infect Dis 2016;22:634–40.

20. Berg ES, Wester AL, Ahrenfeldt J, Mo SS, Slette- meas JS, Steinbakk M, et al. Norwegian patients and retail chicken meat share cephalosporin-resistant Escherichia coli and IncK/blaCMY-2 resistance plasmids. Clin Microbiol Infect 2017;23:407. e9-407. e15

FIRST MCR-1 E. COLI ISOLATE FROM FINLAND

© 2018 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Medical Microbiology and Pathology